Memantine in treatment of Alzheimer’s disease: 20 years of clinical use

Close metadata

Recommended articles:

Prevalence of cognitive impairment in older adults in the Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11

Cognitive impairment in cerebrovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Impairment of attention and executive functions in chronic cerebrovascular disease and Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):25-32

Assessment of the significance of dilated perivascular spaces and nocture arterial hypertension in the development of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):33-40

Traumatic damage to the diaphragm in children. Pirogov Russian Journal of Surgery. 2024;(4):64-68

Glymphatic dysfunction and sleep disorders: indirect effects on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12

Promising approaches to the pathogenetic therapy of amyotrophic lateral sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21

Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27

Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68

Alzheimer’s disease (AD) is a common neurodegenerative disease with progressive course which leads to severe dementia. The author considers the issues of pathogenesis and diagnosis of AD. The efficacy and safety of memantine are analyzed in depth. Recommendations for clinicians on the use of memantine in patients with AD are presented.

Keywords:

dementia

Alzheimer’s disease

memantine

treatment

Authors:

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

List of references:

Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B.The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155-162.
Double A. Pharmacology and Therapeutics. 1999;81:3:163-221.
Greenamyre JT, Young AB, Penney JB. Quantative autoradiographic distribution of L-[3H] glutamate-binding sites in rat central nervous system. Neurosci. 1984;4:2133-2144.
Braak H, Braak E. Pathology of Alzheimer’s disease. In: Calne D.B. (ed.) Neurodegenerative disease. Philadelphia: Saunders; 1994;585-613.
Wenk GL, Danysz W, Mobley SL. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res. 1994;655:7-11.
Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J PharmacEnv Tox Pharmacol. 1995;293:267-270.
Wenk GL, Hauss-Wegrzyniak B, Baker LM. Potential therapies for a novel animal model of Alzheimer’s disease - chronic neuroinflammation of transgenic rats that overexpress human 3-amyloid. Nerobiol Aging. 1998;19:129.
Miguel Hidalgo JJ, Alvarez XA, Quack G, Cacabelos R. Protection by memantine against Ab (1-40)-induced neurodegeneration in CA1 subfield. NeurobiolAging. 1998;19:542.
Gavrilova S.I., Kalyn Ya.B., Kolykhalov I.V., Mikhailova N.M., Roshchina I.F., Selezneva N.D., Zharikov G.A., Radzivill G.G. Akatinol memantin - modulyator glutamatergicheskoi sistemy v lechenii dementsii al'tsgeimerovskogo tipa. Sotsial'n i klinich psikhiatr. 1995;2:78-89.
Ditzer K. Efficacy and tolerability of memantine in patients with dementia syndrome. Drug Res. 1991;41:773-780.
Gortelmeyer R, Erbler H. Memantine in treatment of mild to moderate dementia syndrome. Drug Res. 1992;904-913.
Gortelmeyer R, Pantev M, Parsons CG, Quack G. The treatment of dementia syndrome with Akatinol Memantine, a modulator of the glutamatergic system. In: Wild K. (Hrsq.): Spektrum der Neurorehabilitation; 1993;50-56.
Pantev M, Ritter R, Gortelmeyer R. Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Z Gerontopsychologie und - psychiatric. 1993;6:103-117.
Gottfries CG, Bråne G, Gullberg B, Steen G. A new rating scale for dementia syndromes. Arch Gerontol Geriatr. 1982;1:311-330.
McKhann G, Drachman D, Spano F et al. Clinical diagnosis of Alzheimer`s disease: report of the NINCDS-ADRDA Work Group. Neurology. 1984;146:939-944.
Luriya A.R. Osnovy neiropsikhologii. M.: Izd-vo MGU; 1973.
Roshchina I.F., Gavrilova S.I., Zharikov G.A. i dr. Otsenka effektivnosti terapii akatinolom memantinom bol'nykh s bolezn'yu Al'tsgeimera po rezul'tatam neiropsikhologicheskogo testirovaniya. Psikhiatriya i farmakoterapiya. 2002;6:34-40.
ISS Integrated Summary of Safety for Memantine (Merz + Co.). 2000.
Winblad B, Poritis N, Mobiuss H-J. Clinical improvment in a placebo-controlled trial with memantine in care-dependent patients with severe dementia. In: Ingrad K., Swaab D.F., Winblad B., Wisnievski H.M. (ed.). Alzheimer’s Disease and Related Disorders. Etiology, Pathogenesis and Therapeutics. John Wiley and SonsLtd. 1999;633-639.
Gavrilova S.I., Kalyn Ya.B., Kolykhalov I.V. i dr. Novye vozmozhnosti kholinergicheskoi terapii bolezni Al'tsgeimera. Psikhiatriya. 2005;2:39-47.
Gavrilova S.I., Kalyn Ya.B., Selezneva N.D. i dr. Glutamatergicheskaya terapiya bolezni Al'tsgeimera na stadii umerenno-tyazheloi i tyazheloi dementsii: rezul'taty 26 nedel'nogo issledovaniya effektivnosti i bezopasnosti preparata akatinol memantin. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova. 2005;2:72-76.
Gautheir S, Wirth Y, Möbius HJ. Effects of Memantine in Behavioural Symptoms in Alzheimer’s Disease Patients: An Analysis of the Neuropsychiatric Inventory (NPI) Data of Two Randomized, Controlled Studies. Int J GeriatrPsychiatry. 2005;20:1-6.
Bakchine S. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, doubleblind, placebo-controlled 6-month study. J Alzheimers Dis. 2008;13(1):97-107.
Winblad B, Jones RW, Wirth Y et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomized clinical trials. Dement GeriatrCogn Disord. 2007;24(1):20-27.
Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Metaanalysis of six-month memantine trials in Alzheimer’s disease. Alzheimers Dement. 2007;3(1):7-17. Meta-Analysis of the Efficacy of Memantine in AD 581.
IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Memantine Alzheimer bei Demenz. Abschlussbericht. IQWiG-Berichte-Jahr. 2009;59.
Lundbeck. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of memantine in patients with dementia of the Alzheimer’s type. http://www.lundbecktrialscom.com/Data/PDFs/10116_Final_11Oct2006_CTRSpdf. 2006.
PenTAG. Peninsula Technology Assessment Group (PenTAG), University of Exeter. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease: a systematic review and economic model. 2010. https:// guidance.nice.org.uk/TA/WaveR111/1//AssessmentReport.
Rive B, Gauthier S, Costello S et al. Synthesis and Comparison of Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s disease. CNS Drugs. 2013;27:573-582.
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333-1341.
van Dyck C. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136-143.
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704-715.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324.
Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, doubleblind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-89.

Close metadata